Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis

Medicine & Life Sciences

• 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 100%
• Fibrosis 36%
• End Stage Liver Disease 19%
• Fatty Liver 17%
• Placebos 11%
• Liver 8%
• Study Guides 7%
• Hepatorenal Syndrome 7%
• Portal Pressure 7%
• Caspase Inhibitors 6%
• Carbon Tetrachloride 6%
• Hepatic Encephalopathy 6%
• International Normalized Ratio 6%
• Portal Hypertension 5%
• Peritonitis 5%
• Serum Albumin 5%
• Diuretics 5%
• Ascites 5%
• Double-Blind Method 5%
• Bilirubin 5%
• Sodium 4%
• Hepatocellular Carcinoma 4%
• Clinical Trials 3%
• Hemorrhage 3%
• Apoptosis 3%
• Inflammation 3%
• Mortality 2%
• Therapeutics 2%
• Wounds and Injuries 2%
• Child 2%